AQR Capital Management LLC Has $4.46 Million Stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

AQR Capital Management LLC boosted its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 45.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 684,578 shares of the biotechnology company’s stock after purchasing an additional 214,836 shares during the quarter. AQR Capital Management LLC owned about 0.44% of Ironwood Pharmaceuticals worth $4,463,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Russell Investments Group Ltd. grew its holdings in shares of Ironwood Pharmaceuticals by 244.8% during the first quarter. Russell Investments Group Ltd. now owns 777,847 shares of the biotechnology company’s stock valued at $6,775,000 after buying an additional 552,227 shares during the last quarter. Eventide Asset Management LLC acquired a new position in Ironwood Pharmaceuticals during the 4th quarter valued at about $8,472,000. Entropy Technologies LP bought a new stake in Ironwood Pharmaceuticals during the 1st quarter worth approximately $693,000. First Eagle Investment Management LLC raised its stake in shares of Ironwood Pharmaceuticals by 10.5% in the first quarter. First Eagle Investment Management LLC now owns 1,002,225 shares of the biotechnology company’s stock worth $8,729,000 after purchasing an additional 95,000 shares during the last quarter. Finally, 13D Management LLC lifted its holdings in shares of Ironwood Pharmaceuticals by 971.8% in the fourth quarter. 13D Management LLC now owns 367,649 shares of the biotechnology company’s stock valued at $4,206,000 after purchasing an additional 333,348 shares in the last quarter.

Ironwood Pharmaceuticals Stock Up 1.7 %

IRWD opened at $4.30 on Friday. Ironwood Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $15.70. The company’s 50-day moving average price is $4.81 and its two-hundred day moving average price is $6.29. The stock has a market cap of $673.07 million, a price-to-earnings ratio of -0.63 and a beta of 0.48.

Wall Street Analyst Weigh In

IRWD has been the subject of several recent research reports. Wells Fargo & Company decreased their price target on Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, August 9th. Capital One Financial downgraded shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $12.00 to $4.00 in a report on Thursday, August 8th. Leerink Partnrs upgraded shares of Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 16th. Finally, Craig Hallum cut their target price on Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $12.17.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, insider Minardo John sold 9,910 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $4.27, for a total transaction of $42,315.70. Following the completion of the transaction, the insider now directly owns 284,661 shares of the company’s stock, valued at approximately $1,215,502.47. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 12.90% of the stock is currently owned by insiders.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.